Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]Lu-PSMA-ALB-56
- Development stage
- Unknown
- Lead developer
- Center for Radiopharmaceutical Sciences
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
[177Lu]Lu-PSMA-ALB-56 is a novel radiopharmaceutical designed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is a small-molecule radioligand that targets the prostate-specific membrane antigen (PSMA), which is highly expressed on prostate cancer cells. The molecule is functionalized with a DOTA chelator to carry the beta-emitting radionuclide lutetium-177 and uniquely incorporates a p-tolyl albumin-binding entity. This albumin-binding moiety is designed to extend the circulation time of the drug in the blood, thereby enhancing the accumulation of radioactivity within tumor lesions. Compared to conventional PSMA-targeting agents like PSMA-617, [177Lu]Lu-PSMA-ALB-56 demonstrates significantly higher tumor uptake and absorbed doses, although it also results in higher radiation exposure to the kidneys and red marrow due to its prolonged blood half-life.
- Other names
- 177Lu-PSMA-ALB-56lutetium-177 PSMA-ALB-56lutetium177 PSMA-ALB-56lutetium 177 PSMA-ALB-56Lu-177 PSMA-ALB-56Lu177 PSMA-ALB-56Lu 177 PSMA-ALB-56
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on [177Lu]Lu-PSMA-ALB-56.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [177Lu]Lu-PSMA-ALB-56.